Skip to main content

Common medications increase risk of mild cognitive impairment

A large study of older African-Americans has found taking common medications with anticholinergic effects was correlated with an increased risk of developing mild cognitive impairment.

Anticholinergics are widely used for a variety of common medical conditions including insomnia, allergies, or incontinence, and many are sold over the counter. Now a large six-year study of older African-Americans has found that taking one anticholinergic significantly increased an individual's risk of developing mild cognitive impairment and taking two of these drugs doubled this risk. The risk was greater for those who didn’t have the ‘Alzheimer’s gene’, APOE-e4.

This class of drugs includes Benadryl®, Dramamine®, Excedrin PM®, Nytol®, Sominex®, Tylenol PM®, Unisom®, Paxil®, Detrol®, Demerol® and Elavil® (for a more complete list of medications with anticholinergic effects, go to http://www.indydiscoverynetwork.org/AnticholienrgicCognitiveBurdenScale…).

http://www.sciencedaily.com/releases/2010/07/100713111724.htm
http://www.bbc.co.uk/news/health-10614837

Reference

Campbell, N., Boustani, M., Lane, K. A., Gao, S., Hendrie, H., Khan, B., … Hall, K. (2010). Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology, 75(2), 152-159. Retrieved from http://www.neurology.org/cgi/content/abstract/75/2/152

anticholinergics
seniors
Drugs
aging
MCI
risk factors
Aging

Related News

Antihypertensive drugs may protect against Alzheimer's disease

Two mouse experiments have found that the drug carvedilol, prescribed for the treatment of hypertension, significantly improved synaptic transmission in Alzheimer's disease-type brains, and at a behavioral level significantly improved learning and memory.

Ritalin boosts learning by increasing brain plasticity

A rat study shows how Ritalin improves concentration and, it now appears, speed of learning. The study reveals that it does this by increasing the activity of dopamine at two specific types of neurotransmitter receptors in the amygdala. The dopamine receptor tagged “D2” appears to control the ability to stay focused on a task, while the D1 receptor underlies learning efficiency. The finding may help the development of better-targeted drugs.